QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 18 January 2005
doi: 10.1242/jcs.01641

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jcs.01641v1 118/3/555    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, L. Articles by Shu, H.-B. Search for Related Content PubMed PubMed Citation Articles by Li, L. Articles by Shu, H.-B.

TRIP6 is a RIP2-associated common signaling component of multiple NF-B activation pathways

¹ Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China
² Department of Immunology, National Jewish and Research Center, University of Colorado Health Sciences Center, 1400 Jackson Street, Denver, CO 80206, USA

^* Author for correspondence (e-mail: shuh{at}njc.org)

Accepted 10 November 2004

Receptor-interacting protein 2 (RIP2) is a member of the RIP kinase family that has been shown to be crucially involved in inflammation, innate and adaptive immune responses. The physiological and pathological roles of RIP2 are mediated through its involvement in multiple NF-B activation pathways, including those triggered by tumor necrosis factor (TNF), interleukin 1 (IL-1), Toll-like receptor 2 (TLR2), TLR3, TLR4 and Nod1. In this report, we identified the LIM-domain-containing protein TRIP6 as a RIP2-interacting protein in yeast two-hybrid screens. In mammalian cells, TRIP6 interacts with RIP2 in a TNF- or IL-1-dependent manner. Overexpression of TRIP6 potentiates RIP2-mediated NF-B activation in a dose-dependent manner. The LIM domains of TRIP6 are responsible for its interaction with RIP2. TRIP6 also interacts with TRAF2, a protein that is crucially involved in TNF signaling, as well as the IL-1 receptor, TLR2 and Nod1. Overexpression of TRIP6 potentiates NF-B activation by TNF, IL-1, TLR2 or Nod1, whereas a dominant negative mutant or RNA-interference construct of TRIP6 inhibits NF-B activation by TNF, IL-1, TLR2 or Nod1. Moreover, TRIP6 also potentiates RIP2- and Nod1-mediated ERK activation. These data have established a physical and functional association between TRIP6 and RIP2, and suggest that RIP2's involvement in multiple NF-B and ERK activation pathways is mediated through TRIP6.

Key words: RIP2, TRIP6, NF-B, TNF, IL1, Nod1

This article has been cited by other articles:

				K. R. Buchholz and R. S. Stephens The Cytosolic Pattern Recognition Receptor NOD1 Induces Inflammatory Interleukin-8 during Chlamydia trachomatis Infection Infect. Immun., July 1, 2008; 76(7): 3150 - 3155. [Abstract] [Full Text] [PDF]

				N. Takizawa, T. C. Smith, T. Nebl, J. L. Crowley, S. J. Palmieri, L. M. Lifshitz, A. G. Ehrhardt, L. M. Hoffman, M. C. Beckerle, and E. J. Luna Supervillin modulation of focal adhesions involving TRIP6/ZRP-1 J. Cell Biol., July 31, 2006; 174(3): 447 - 458. [Abstract] [Full Text] [PDF]

				T. J. Lukas, W. W. Luo, H. Mao, N. Cole, and T. Siddique Informatics-assisted Protein Profiling in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis Mol. Cell. Proteomics, July 1, 2006; 5(7): 1233 - 1244. [Abstract] [Full Text] [PDF]